Evidence map›Paper›PMID 41051694›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2025

Efficacy and Safety of Once-Weekly Insulin Icodec in Indian Participants with Diabetes: Results from ONWARDS 1, 4, and 6 Studies.

Viswanathan Mohan, Jothydev Kesavadev, L Sreenivasa Murthy, Gayathri Anil, Manu Chandrappa, Soumitra Kar, Sunil Mishra

3 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04460885 phase3completednot on this map

A 78-week Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Glargine 100 Units/mL, Both in Combination With Non-insulin Anti-diabetic Treatment, in Insulin naïve Subjects With Type 2 Diabetes

TypeinterventionalSponsorNovo Nordisk A/SRan2020 to 2022Enrolled984ConditionsDiabetes Mellitus, Type 2ArmsInsulin icodec, Insulin glargine
NCT04848480 phase3completednot on this map

Efficacy and Safety of Once Weekly Insulin Icodec Compared to Once Daily Insulin Degludec 100 Units/mL, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes. A 26-week, Randomised, Multicentre, Open-label, Active-controlled, Parallel Group, Two Armed, Treat-to-target Trial Investigating the Effect on Glycaemic Control and Safety of Treatment With Once Weekly Insulin Icodec Compared to Once Daily Insulin Degludec, Both in Combination With Insulin Aspart in Adults With Type 1 Diabetes, With a 26-week Extension Investigating Long Term Safety

TypeinterventionalSponsorNovo Nordisk A/SRan2021 to 2022Enrolled582ConditionsDiabetes Mellitus, Type 1Armsinsulin icodec, insulin degludec, insulin aspart
NCT04880850 phase3completednot on this map

A 26-week Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Glargine 100 Units/mL, Both in Combination With Bolus Insulin With or Without Non-insulin Anti-diabetic Drugs, in Subjects With Type 2 Diabetes on a Basal-bolus Regimen

TypeinterventionalSponsorNovo Nordisk A/SRan2021 to 2022Enrolled582ConditionsDiabetes Mellitus, Type 2ArmsInsulin icodec, Insulin glargine, Insulin aspart
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Viswanathan MohanDr. Mohan's Diabetes Specialities Centre (IDF Centre of Excellence in Diabetes Care) and Madras Diabetes Research Foundation (ICMR Collaborating Centre of Excellence), Chennai, Tamil Nadu, India. drmohans@diabetes.ind.in.ORCID http://orcid.org/0000-0001-5038-6210
Jothydev KesavadevJothydev's Diabetes Research Center, Kochi, Trivandrum, India.
L Sreenivasa MurthyLife Care Hospital and Research Centre, Bengaluru, India.
Gayathri AnilNovo Nordisk Service Centre India Private Ltd., Bengaluru, India.
Manu ChandrappaNovo Nordisk Singapore Pvt. Ltd, Singapore, Singapore.
Soumitra KarNovo Nordisk Service Centre India Private Ltd., Bengaluru, India.
Sunil MishraGraphic Era Institute of Medical Sciences, Dehradun, Uttarakhand, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThese analyses explored the efficacy and safety of once-weekly insulin icodec (icodec) in Indian participants with type 1 or type 2 diabetes (T1D/T2D) from the global ONWARDS 1, 4, and 6 studies.

methodsThis was a subgroup analysis of Indian participants enrolled in the multicentre, randomised, treat-to-target phase 3a studies: ONWARDS 1 (insulin-naïve T2D), ONWARDS 4 (basal-bolus treated T2D), and ONWARDS 6 (basal-bolus treated T1D). Participants were randomised 1:1 to receive once-weekly insulin icodec or once-daily comparator insulin (glargine U100 [ONWARDS 1 and 4] or degludec [ONWARDS 6]). The primary outcome was change in glycated haemoglobin (HbA

resultsA total of 217 Indian participants were included. The estimated treatment differences (95% confidence interval, CI) in HbA

conclusionIcodec demonstrated comparable efficacy and safety to once-daily basal insulins in Indian participants with T1D and T2D. These findings support icodec as a viable option for insulin initiation or intensification in Indian clinical practice. TRIAL REGISTRATIONS: ONWARDS 1: NCT04460885; ONWARDS 4: NCT04880850; ONWARDS 6: NCT04848480.

Indexed as

Basal insulinIndian subpopulationInsulin icodecOnce-weekly insulinType 1 diabetesType 2 diabetes

Identifiers

PMID41051694
PMCPMC12579031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.